Pershing Square Announces IPO Pricing for PSUS and PS Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Should l Buy PS?
Pershing Square USA, an investment company managed by Pershing Square Capital Management, and Pershing Square Inc., the parent company of PSCM, announced the pricing of the combined initial public offering of the common shares of beneficial interest of PSUS and the initial public offering of the common stock of PSI. The PSUS Shares and the PSI Shares are expected to begin trading on the New York Stock Exchange under the symbol "PSUS" for the PSUS Shares and under the symbol "PS" for the PSI Shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PS
Wall Street analysts forecast PS stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 24.000
Low
Averages
High
Current: 24.000
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pershing Square Announces $5 Billion IPO
- IPO Size: Pershing Square USA, Ltd. announced a combined initial public offering (IPO) size of $5 billion, expected to begin trading on the New York Stock Exchange on April 29, 2026, marking a significant advancement for the company in capital markets.
- Trading Symbols: The PSUS and PSI shares will trade under the symbols 'PSUS' and 'PS' on the NYSE, providing new investment opportunities for investors while potentially enhancing the company's market visibility and attractiveness.
- Financing Structure: The IPO, combined with the previously announced private placement, is expected to generate $5 billion in gross proceeds for PSUS before deducting fees, which will provide robust funding support for the company's investment operations.
- Regulatory Compliance: The registration statements related to the securities sold in the Combined IPO were declared effective by the U.S. Securities and Exchange Commission on April 28, 2026, ensuring compliance and further bolstering investor confidence.
See More
Bill Ackman's PSUS IPO Opens Below Price, Signals Weak Demand
- IPO Performance: Bill Ackman's Pershing Square USA (PSUS) debuted on the NYSE at approximately $41, opening 18% below its $50 IPO price, indicating weak market demand for the investment vehicle.
- Investor Return Structure: Each investor participating in the IPO received one share of its management company, Pershing Square (PS), for every five common shares of PSUS purchased, a strategy aimed at enhancing investor appeal but failing to boost market confidence effectively.
- Market Reaction: The opening price of PSUS fell short of expectations, with earlier predictions suggesting an opening range of $42.5 to $47.5, reflecting cautious investor sentiment regarding the company's future prospects.
- Funding Target: Despite the poor IPO performance, PSUS is still expected to raise approximately $5 billion, which will support its investment strategies and future growth, demonstrating Ackman's long-term confidence in the market.
See More
Pershing Square USA Raises $5 Billion in Record Fund Launch
- Record Fundraising: Pershing Square USA successfully raised $5 billion by selling 100 million shares at $50 each, marking the largest launch of a new closed-end fund in history, reflecting strong market confidence in its long-term investment strategy.
- Diverse Investor Base: The fundraising included $2.2 billion from public investors through a registered offering and $2.8 billion from private placements, attracting a wide range of investors such as family offices (30%), pension funds (25%), and insurance companies (22%), indicating broad appeal across different investor segments.
- Long-Term Capital Advantage: The fund's permanent capital structure allows management to adopt a long-term view during market volatility, avoiding forced asset sales due to redemption demands, thereby enhancing flexibility and stability in uncertain market conditions.
- Management Company IPO: In addition to the closed-end fund, Ackman is taking public the management company, Pershing Square Inc., on the NYSE, where investors purchasing PSUS will receive shares of PS, further enhancing investor engagement and potential returns through this innovative listing approach.
See More
Ackman's $5 Billion IPO Launches with Berkshire-like Ambitions
- Reduced IPO Scale: Ackman's initial public offering raised $5 billion, which, while below the initial target of $10 billion, still represents a significant step towards his ambition of building a Berkshire Hathaway-like investment platform.
- Dual Trading Structure: The transaction creates two separately traded entities on the New York Stock Exchange: closed-end fund Pershing Square USA Ltd. (ticker: PSUS) and asset manager Pershing Square Inc. (ticker: PS), allowing investors to choose between exposure to the underlying portfolio or the management business.
- Innovative Investor Structure: Priced at $50 per share, the offering is structured to appeal to both institutional and retail investors while notably omitting performance fees, ensuring retail investors have similar opportunities as institutional ones, reflecting Ackman's commitment to ordinary investors.
- Long-Term Return Advantage: Since its inception in 2004, Pershing Square has generated cumulative net returns exceeding 2,600%, significantly outpacing the S&P 500's 836% gain during the same period, showcasing the effectiveness of its macro hedging strategies during market dislocations, thereby enhancing investor confidence.
See More
Ackman's Firms Set to Launch $5 Billion IPOs
- IPO Scale and Timing: Ackman's Pershing Square USA and Pershing Square Inc. are set to complete their IPOs on April 30, aiming for a total fundraising of $5 billion, with approximately $2.8 billion already committed by large investors, although falling short of the $10 billion target.
- Exchange Listing Details: Pershing Square USA will trade on the New York Stock Exchange under the symbol PSUS, while Pershing Square Inc. will be listed as PS, marking Ackman's renewed entry into the capital markets aimed at attracting more investors.
- Investor Incentive Mechanism: Ackman announced that investors purchasing shares of Pershing Square USA will receive one share of Pershing Square Inc. for every five shares bought, a strategy designed to enhance investor participation and market appeal.
- Management Fee Structure: Pershing Square USA will charge a 2% management fee while forgoing performance fees, a fee structure that may attract investors seeking stable returns and reflects the company's strategic response to market competition.
See More
Upcoming IPOs: Biotech Firms Set to Raise Capital
- Biotech Fundraising Plans: Neuropsychiatric therapeutics biotech Seaport Therapeutics (SPTX) plans to raise $201 million at a $976 million market cap, with lead programs including GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder, indicating its potential in the mental health sector.
- Pulmonary Fibrosis Treatment Progress: Pulmonary fibrosis biotech Avalyn Pharma (AVLN) is also set to raise $201 million at a $683 million market cap, with advanced candidates AP01 and AP02 undergoing global Phase 2b trials, with key data expected in mid to late 2027, potentially enhancing its market position.
- Coagulation Disorder R&D: Hemab Therapeutics (COAG) plans to raise $200 million at a $715 million market cap, developing antibody therapies for inherited bleeding and coagulation disorders, with its lead candidate HMB-001 having completed Phase 2 and ready for Phase 3, reflecting strong market demand.
- Mining Company IPO Plans: Exploration-stage Silver Bow Mining (SBMT) is tentatively scheduled to raise $50 million at a $358 million market cap, focusing on silver, zinc, gold, lead, and copper in Montana, and while it has yet to generate revenue, its mineral resource potential is attracting attention.
See More
Pershing Square Announces $5 Billion IPO
- IPO Size: Pershing Square USA, Ltd. announced a combined initial public offering (IPO) size of $5 billion, expected to begin trading on the New York Stock Exchange on April 29, 2026, marking a significant advancement for the company in capital markets.
- Trading Symbols: The PSUS and PSI shares will trade under the symbols 'PSUS' and 'PS' on the NYSE, providing new investment opportunities for investors while potentially enhancing the company's market visibility and attractiveness.
- Financing Structure: The IPO, combined with the previously announced private placement, is expected to generate $5 billion in gross proceeds for PSUS before deducting fees, which will provide robust funding support for the company's investment operations.
- Regulatory Compliance: The registration statements related to the securities sold in the Combined IPO were declared effective by the U.S. Securities and Exchange Commission on April 28, 2026, ensuring compliance and further bolstering investor confidence.
See More
Bill Ackman's PSUS IPO Opens Below Price, Signals Weak Demand
- IPO Performance: Bill Ackman's Pershing Square USA (PSUS) debuted on the NYSE at approximately $41, opening 18% below its $50 IPO price, indicating weak market demand for the investment vehicle.
- Investor Return Structure: Each investor participating in the IPO received one share of its management company, Pershing Square (PS), for every five common shares of PSUS purchased, a strategy aimed at enhancing investor appeal but failing to boost market confidence effectively.
- Market Reaction: The opening price of PSUS fell short of expectations, with earlier predictions suggesting an opening range of $42.5 to $47.5, reflecting cautious investor sentiment regarding the company's future prospects.
- Funding Target: Despite the poor IPO performance, PSUS is still expected to raise approximately $5 billion, which will support its investment strategies and future growth, demonstrating Ackman's long-term confidence in the market.
See More
Pershing Square USA Raises $5 Billion in Record Fund Launch
- Record Fundraising: Pershing Square USA successfully raised $5 billion by selling 100 million shares at $50 each, marking the largest launch of a new closed-end fund in history, reflecting strong market confidence in its long-term investment strategy.
- Diverse Investor Base: The fundraising included $2.2 billion from public investors through a registered offering and $2.8 billion from private placements, attracting a wide range of investors such as family offices (30%), pension funds (25%), and insurance companies (22%), indicating broad appeal across different investor segments.
- Long-Term Capital Advantage: The fund's permanent capital structure allows management to adopt a long-term view during market volatility, avoiding forced asset sales due to redemption demands, thereby enhancing flexibility and stability in uncertain market conditions.
- Management Company IPO: In addition to the closed-end fund, Ackman is taking public the management company, Pershing Square Inc., on the NYSE, where investors purchasing PSUS will receive shares of PS, further enhancing investor engagement and potential returns through this innovative listing approach.
See More
Ackman's $5 Billion IPO Launches with Berkshire-like Ambitions
- Reduced IPO Scale: Ackman's initial public offering raised $5 billion, which, while below the initial target of $10 billion, still represents a significant step towards his ambition of building a Berkshire Hathaway-like investment platform.
- Dual Trading Structure: The transaction creates two separately traded entities on the New York Stock Exchange: closed-end fund Pershing Square USA Ltd. (ticker: PSUS) and asset manager Pershing Square Inc. (ticker: PS), allowing investors to choose between exposure to the underlying portfolio or the management business.
- Innovative Investor Structure: Priced at $50 per share, the offering is structured to appeal to both institutional and retail investors while notably omitting performance fees, ensuring retail investors have similar opportunities as institutional ones, reflecting Ackman's commitment to ordinary investors.
- Long-Term Return Advantage: Since its inception in 2004, Pershing Square has generated cumulative net returns exceeding 2,600%, significantly outpacing the S&P 500's 836% gain during the same period, showcasing the effectiveness of its macro hedging strategies during market dislocations, thereby enhancing investor confidence.
See More
Ackman's Firms Set to Launch $5 Billion IPOs
- IPO Scale and Timing: Ackman's Pershing Square USA and Pershing Square Inc. are set to complete their IPOs on April 30, aiming for a total fundraising of $5 billion, with approximately $2.8 billion already committed by large investors, although falling short of the $10 billion target.
- Exchange Listing Details: Pershing Square USA will trade on the New York Stock Exchange under the symbol PSUS, while Pershing Square Inc. will be listed as PS, marking Ackman's renewed entry into the capital markets aimed at attracting more investors.
- Investor Incentive Mechanism: Ackman announced that investors purchasing shares of Pershing Square USA will receive one share of Pershing Square Inc. for every five shares bought, a strategy designed to enhance investor participation and market appeal.
- Management Fee Structure: Pershing Square USA will charge a 2% management fee while forgoing performance fees, a fee structure that may attract investors seeking stable returns and reflects the company's strategic response to market competition.
See More
Upcoming IPOs: Biotech Firms Set to Raise Capital
- Biotech Fundraising Plans: Neuropsychiatric therapeutics biotech Seaport Therapeutics (SPTX) plans to raise $201 million at a $976 million market cap, with lead programs including GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder, indicating its potential in the mental health sector.
- Pulmonary Fibrosis Treatment Progress: Pulmonary fibrosis biotech Avalyn Pharma (AVLN) is also set to raise $201 million at a $683 million market cap, with advanced candidates AP01 and AP02 undergoing global Phase 2b trials, with key data expected in mid to late 2027, potentially enhancing its market position.
- Coagulation Disorder R&D: Hemab Therapeutics (COAG) plans to raise $200 million at a $715 million market cap, developing antibody therapies for inherited bleeding and coagulation disorders, with its lead candidate HMB-001 having completed Phase 2 and ready for Phase 3, reflecting strong market demand.
- Mining Company IPO Plans: Exploration-stage Silver Bow Mining (SBMT) is tentatively scheduled to raise $50 million at a $358 million market cap, focusing on silver, zinc, gold, lead, and copper in Montana, and while it has yet to generate revenue, its mineral resource potential is attracting attention.
See More
